Johnson & Johnson (NYSE:JNJ) issued its earnings results on Tuesday. The company reported $2.10 EPS for the quarter, topping analysts’ consensus estimates of $2.06 by $0.04, MarketWatch Earnings reports. Johnson & Johnson had a return on equity of 35.63% and a net margin of 18.75%. The firm had revenue of $20.02 billion for the quarter, compared to the consensus estimate of $19.55 billion. During the same quarter in the prior year, the business earned $2.06 earnings per share. The company’s revenue was up .1% compared to the same quarter last year. Johnson & Johnson updated its FY 2019 guidance to $8.53-8.63 EPS and its FY19 guidance to $8.53-8.63 EPS.
Shares of JNJ stock opened at $138.02 on Wednesday. The company has a market cap of $370.29 billion, a price-to-earnings ratio of 16.87, a price-to-earnings-growth ratio of 2.21 and a beta of 0.68. The company has a current ratio of 1.47, a quick ratio of 1.20 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a 12-month low of $118.62 and a 12-month high of $148.99.
JNJ has been the topic of a number of recent research reports. Zacks Investment Research downgraded Johnson & Johnson from a “hold” rating to a “sell” rating in a research note on Wednesday, January 16th. Citigroup lowered their target price on Johnson & Johnson from $148.00 to $139.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 2nd. Wells Fargo & Co restated an “outperform” rating and issued a $152.00 target price (down previously from $162.00) on shares of Johnson & Johnson in a research note on Monday, January 14th. Barclays restated an “equal weight” rating and issued a $135.00 target price (down previously from $137.00) on shares of Johnson & Johnson in a research note on Wednesday, January 23rd. Finally, Morgan Stanley set a $140.00 target price on Johnson & Johnson and gave the stock a “hold” rating in a research note on Thursday, December 20th. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $143.58.
Hedge funds have recently modified their holdings of the business. Fundsmith Equity Fund L.P. bought a new stake in shares of Johnson & Johnson during the second quarter worth $552,762,000. Chicago Partners Investment Group LLC grew its position in Johnson & Johnson by 3.7% in the second quarter. Chicago Partners Investment Group LLC now owns 12,011 shares of the company’s stock valued at $1,457,000 after purchasing an additional 431 shares in the last quarter. Ashburton Jersey Ltd grew its position in Johnson & Johnson by 6.0% in the second quarter. Ashburton Jersey Ltd now owns 145,725 shares of the company’s stock valued at $17,682,000 after purchasing an additional 8,196 shares in the last quarter. Exane Asset Management bought a new position in Johnson & Johnson in the second quarter valued at $206,000. Finally, SP Asset Management bought a new position in Johnson & Johnson in the second quarter valued at $11,792,000. Institutional investors own 67.32% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Recommended Story: Quick Ratio
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.